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Abstract
Background: Cancer chemotherapy is frequently associated with a decline in general physical condition, exercise
tolerance, and muscle strength and with an increase in fatigue. While accumulating evidence suggests that
physical activity and exercise interventions during chemotherapy treatment may contribute to maintaining
cardiorespiratory fitness and strength, the results of studies conducted to date have not been consistent.
Additional research is needed to determine the optimal intensity of exercise training programs in general and in
particular the relative effectiveness of supervised, outpatient (hospital- or physical therapy practice-based) versus
home-based programs.
Methods: This multicenter, prospective, randomized trial will evaluate the effectiveness of a low to moderate
intensity, home-based, self-management physical activity program, and a high intensity, structured, supervised
exercise program, in maintaining or enhancing physical fitness (cardiorespiratory fitness and muscle strength), in
minimizing fatigue and in enhancing the health-related quality of life (HRQoL). Patients receiving adjuvant
chemotherapy for breast or colon cancer (n = 360) are being recruited from twelve hospitals in the Netherlands,
and randomly allocated to one of the two treatment groups or to a ‘usual care’ control group. Performance-based
and self-reported outcomes are assessed at baseline, at the end of chemotherapy and at six month follow-up.
Discussion: This large, multicenter, randomized clinical trial will provide additional empirical evidence regarding
the effectiveness of physical exercise during adjuvant chemotherapy in enhancing physical fitness, minimizing
fatigue, and maintaining or enhancing patients’ quality of life. If demonstrated to be effective, exercise intervention
programs will be a welcome addition to the standard program of care offered to patients with cancer receiving
chemotherapy.
Trial registration: This study is registered at the Netherlands Trial Register (NTR 2159).
Background
Treatment with chemotherapy is associated with multiple
physical and psychosocial side effects, including reduced
cardiorespiratory fitness and muscle strength and increased
fatigue [1,2]. Fatigue is a common problem reported by
patients undergoing chemotherapy, with prevalence rates
ranging from 80% to 100% [3-5]. Among breast cancer sur-
vivors, the prevalence of chronic, severe fatigue has been
reported to range from 24% to 40%. Chronic fatigue has a
negative impact on activities of daily life, social reintegra-
tion and overall quality of life [3]. Fatigue and muscle wast-
ing may be directly therapy-induced, but may also be
attributed in part to sedentary habits and subsequent loss* Correspondence: n.aaronson@nki.nl1The Netherlands Cancer Institute, Division of Psychosocial Research and
Epidemiology, Amsterdam, The Netherlands
Full list of author information is available at the end of the article
van Waart et al. BMC Cancer 2010, 10:673
http://www.biomedcentral.com/1471-2407/10/673
© 2010 van Waart et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
of physical fitness (cardiorespiratory fitness and muscle
strength) [6].
There is accumulating evidence that exercise interven-
tions during chemotherapy may contribute to preserving
cardiorespiratory fitness [7-14] and muscle strength
[13,15,16], decreasing fatigue [13,14,17-19], mood distur-
bances [13,14,17,18] and lean body mass [13], and
enhancing self-reported functioning [18], overall HRQoL
[13,14,18] and immune-function [17].
However, results of studies to date have not been
entirely consistent [17,18,20], which may be due, in part,
to methodological limitations. Most studies have
employed small sample sizes (ranging from 6 to 60
patients in the intervention arm) and some have failed
to include a control group. Furthermore, the interven-
tions employed in these studies varied widely. Some stu-
dies have investigated low intensity, home-based
exercise programs, while others report on intensive,
structured and supervised training, with or without
resistance training [14]. Most of the previous studies
employed exercise programs that are less than optimal
in terms of important aspects of exercise physiology
[17]. It is hypothesized that an intervention that com-
bines resistance training and aerobic exercise may be
most effective [15].
Adherence to exercise interventions is a challenging
task [20]. When shaping an exercise program to the
needs of the individual patient, current fitness level,
health beliefs and health behavior need to be taken into
consideration, while still maintaining a core, standar-
dized program that can be relatively easily implemented
in a range of health care settings [20].
Effects of exercise interventions may be moderated by
exercise history and health beliefs. It is likely that socio-
demographic, medical variables, and patients’ prefer-
ences also moderate the effects of exercise interventions
during chemotherapy [21,22].
It should be noted that most trials are characterized
by low participation rates (as low as 17% of potentially
eligible patients), which may limit the generalizability of
the results, particularly if those included in the trial
tended to be more habitually active, more highly moti-
vated and/or better educated than the target population
as a whole [13,14].
Finally, to our knowledge, no study to date, has evalu-
ated the cost-effectiveness of exercise interventions dur-
ing chemotherapy.
In summary, while there is evidence supporting the
beneficial effects of exercise programs during che-
motherapy, the results across studies are not entirely
consistent. Additional studies are needed to determine
the optimal content, intensity, and form of exercise
training programs. Specifically, there is need for research
that investigates an exercise program that combines
aerobic exercise and muscle strength training, as well as
the relative effectiveness of supervised, outpatient versus
unsupervised home-based programs. Such research
should also consider the possible moderating effect of
exercise history, current levels of fitness and physical
activity, health attitudes, and motivation on physical
exercise program effectiveness. The sample size and
thus power of future trials should be sufficient to be
able to demonstrate program effectiveness and cost-
effectiveness based on both physiological performance
measures, and fatigue.
In this article, we describe the design of a randomized,
controlled, multicenter clinical trial comparing: (1) a low
to moderate intensity, home-based, self-management
physical activity program (Onco-Move), (2) a high inten-
sity, structured, supervised exercise program (OnTrack)
and (3) usual care control group, in patients undergoing
adjuvant chemotherapy for breast or colon cancer.
We hypothesize that patients who undergo the Onco-
Move or the OnTrack program will achieve better phy-
sical fitness levels, as assessed by objective performance
tests, will report less fatigue, less mood disturbance,
higher levels of physical activity and functioning in daily
life, and better HRQoL than patients in the usual care
control group. Furthermore, we hypothesize that
patients in the OnTrack program will achieve more
muscle strength and achieve greater gains in cardiore-
spiratory fitness than patients who follow the Onco-
Move program. No differences are expected between the
two programs in self-reported outcomes during treat-
ment. However, it is hypothesized that, at the six month
follow-up, patients who participated in the OnTrack
program will report less fatigue, and higher levels of
physical activity and functioning than those who partici-
pated in the Onco-Move program or usual care control
group. Finally, we hypothesize that the OnTrack and
Onco-Move programs will lead to a reduction in health
care costs, patient and family costs, and costs of produc-
tion losses, resulting in an cost-effective intervention.
If demonstrated to be effective, the availability of such
physical activity and exercise intervention programs will
be a welcome addition to the standard program of care
offered to patients with cancer undergoing chemotherapy.
Methods
The present trial is one of four randomized controlled
trials included in the Alpe d’HuZes Cancer Rehabilita-
tion (A-CaRe) program. All studies within the A-CaRe
program will evaluate the effectiveness and the cost-
effectiveness of exercise-based rehabilitation interven-
tions in different cancer patient and survivor groups. In
the PACES study, patients are being randomized to one
of three study arms. They will participate either in the
Onco-Move or the OnTrack program, or will undergo
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usual care. The design of the trial and the anticipated
flow of the participants are displayed graphically in
Figure 1. The trial has been approved by the institu-
tional review board of the Netherlands Cancer Institute
(under number PTC 09.2711), as well as by the review
boards of all hospitals from which patients are being
recruited. This protocol follows the CONSORT guide-
lines [23]. Patient recruitment and data collection for
this trial started in April, 2010.
Study sample
The study sample will be composed of patients with his-
tologically confirmed primary breast or colon cancer
who are scheduled to undergo adjuvant chemotherapy.
There is no upper age limit for study participation.
Potentially eligible patients are screened for the pre-
sence of comorbid conditions that would contraindicate
participation in a physical activity/exercise program.
This includes patients with serious orthopedic condi-
tions that would hamper functional recovery, and
patients with serious cardiovascular or cardiopulmonary
conditions (or risks) who would not be able to train at
the intensity level required. Patients suffering from mal-
nutrition as evidenced by a BMI < 18 kg/m2, unintended
weight loss of more than 5% per month, or more than
10% unintended weight loss during the previous six
month period are considered poor candidates for physi-
cal condition training and thus are not eligible for parti-
cipation. Patients judged to have serious psychiatric or
cognitive problems that would preclude them from pro-
gram participation are excluded from the study. For
assessment purposes, study participants need to have
basic fluency in the Dutch language. Finally, patients
participating in concurrent studies or rehabilitation pro-
grams containing elements of physical activity or exer-
cise are also ineligible for the study.
Recruitment and randomization
In total 360 patients are being recruited from twelve com-
munity or university hospitals in the wider Amsterdam
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Figure 1 Overview of study procedures.
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region of the Netherlands. All potentially eligible patients
are identified by their medical oncologist or nurse practi-
tioner, and receive written information about the trial.
The patients are contacted by telephone to provide addi-
tional information about the trial and to confirm their
eligibility. If the patient chooses to participate in the trial,
(s)he is invited for an intake session where written
informed consent is obtained and baseline assessments are
made. Subsequently, patients are assigned to one of the
three study groups by means of the minimization method
[24], which is balanced on age, primary diagnosis, treating
hospital and the use of trastuzumab.
Patients who decline to participate in the trial are
asked to complete a one-time questionnaire assessing
basic sociodemographic, attitudinal, and behavioral data,
and to determine the reason(s) for non-participation.
Interventions
Patients are randomized to one of three study groups:
Onco-Move, OnTrack, or usual care. The Onco-Move
program aims at preserving cardiorespiratory fitness, as
advocated by Mock [25]. The OnTrack program com-
bines exercise for both cardiorespiratory fitness and
muscle strength, as advocated by Courneya [15]. Both
the Onco-Move and OnTrack program start in the week
of the first cycle of chemotherapy and continue until
three weeks after the last cycle of chemotherapy. At the
end of chemotherapy all patients receive a leaflet provid-
ing encouragement and information on ways to be
active.
Onco-Move
Onco-Move is a relatively low intensity, home-based,
individualized, self-managed physical activity program
developed and tested in a pilot study by the Compre-
hensive Cancer Centre Amsterdam (IKA). Based on the
“Every Step Counts” program of Mock [25,26], it uses
self-management principles, aiming to maintain general
physical fitness and preventing fatigue.
Trained nurses encourage patients to pursue an active
lifestyle, 30 minutes per day, throughout the chemother-
apy treatment, starting at the first chemotherapy session.
Activities depend on patient preference, which may
include walking, cycling, fitness training or swimming.
Training with weights is not encouraged. At the first
chemotherapy session, patients receive both verbal and
written information about physical activity training, and
specific advice about the desired intensity of activity
based on the Borg Scale of perceived exertion (recom-
mended level 12-14) [27]. The written information is
based on the transtheoretical model of behavior [28,29],
called “active living” which identifies different stages of
activity (pre-contemplation, contemplation, action, and
maintenance).
The information patients receive about physical activ-
ity is tailored to their activity stage. For example,
patients in the contemplation stage receive more infor-
mation on why and how to become active, while
patients in the maintenance stage receive information
on how to stay active [28,29]. Two weeks after the start
of the program the nurse contacts the patient by tele-
phone to inquire about how the program is going and if
there is any additional information or advice needed. At
each subsequent chemotherapy cycle, the nurse dis-
cusses program progress with the patient. Patients are
asked to keep daily activity diaries, both to help them to
monitor their own progress, and as an aid for the nurse
to facilitate optimal use of the program.
OnTrack
The OnTrack is a relatively high intensity exercise pro-
gram which is supervised by a physical therapist in an
outpatient or general physical therapy practice setting.
The pilot study showed that OnTrack was feasible in
patients undergoing chemotherapy [30]. We are making
use of the Onconet network of physical therapists in the
region of North Holland who received special training
in the OnTrack program. This facilitates patients to
undergo the OnTrack program as close to home as
possible.
In this program, patients are encouraged to be physi-
cally active for at least 30 minutes per day at Borg level
12-14 [27]. Like the Onco-Move program, patients are
asked to keep a daily activity dairy. The physical thera-
pists use the “active living” method to encourage daily
physical activity. The physical therapist reviews the daily
activity diary with the patient every three weeks.
Additionally, patients attend supervised exercise ses-
sions two times per week. These sessions comprise exer-
cises for warming up followed by exercises to maintain
or increase muscle strength and exercises to maintain or
increase aerobic capacity. Muscle strength exercises are
performed for 20 minutes per session, starting with two
series of 12 repetitions at 70% of the one repetition
maximum (1RM) per exercise and increasing gradually
to two series of eight repetitions at 80%1RM. Exercising
in sets of two series is considered a sufficient, yet time
efficient means of enhancing muscle strength, ensuring
that all exercises can be performed during a session
[31]. The resistance program consists of at least six
exercises targeting the large muscle groups as follows: 1)
vertical row (longissimus, biceps brachii, rhomboideus);
2) leg press (quadriceps, glutei, gastrocnemius); 3) bench
press (pectoralis major, triceps); 4) pull over (pectoralis,
triceps brachii, deltoideus, trapezius); 5) abdominal
crunch (rectus abdominis); and 6) lunge (quadriceps,
glutei, hamstrings). Additional exercises can be added
according to patients’ preferences.
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For patients with breast cancer who have had axillary
lymph node dissection, a modified strength training pro-
gram is used for the upper extremities, consisting of two
series of 15 repetitions for each exercise with the light-
est possible weight, which is increased with the smallest
possible step when the two series can be completed
without symptoms of lymph edema [32].
Aerobic exercises are performed for 30 minutes per
session (with a minimal duration of ten minutes per exer-
cise), with an intensity of 50% to 80% of the maximal
workload (Wmax) as estimated by the Steep Ramp Test
[33]. The intensity of the aerobic exercises are increased
if a patient scores a 12 or lower on the Borg scale of per-
ceived exertion, while the intensity is decreased at a score
of 16 or higher [27]. The heart rate should be within a
heart rate zone of 60% to 90% of the maximal heart rate,
which is conventionally estimated as 220 minus age.
Usual care
Usual care will vary according to hospital guidelines and
doctors’ and patients’ preferences. Although usual care
can not be standardized, it will not involve routine, sys-
tematic exercises.
Study outcomes
All study outcomes, with the exception of return to
work, compliance and satisfaction with the interven-
tions, are assessed prior to randomization (T0), at the
completion of chemotherapy (T1), and at 6 month fol-
low-up (T2). Return to work is assessed at T1 and T2,
while compliance and satisfaction are assessed at T1
only, and only in the two intervention groups.
To facilitate comparison of results across the A-CaRe
studies, the outcome measures used in these four clini-
cal trials have been harmonized to as great an extent as
possible.
Primary outcome measures
Cardiorespiratory fitness
Cardiorespiratory fitness is being assessed with the steep
ramp test (an incremental bicycle ergometer test) and a
cycle endurance test. Both tests are completed on a cali-
brated, electronically-braked cycle ergometer (Corival,
Lode, Groningen, The Netherlands). For the steep ramp
test, the patient is instructed to cycle at a speed between
70 and 80 revolutions per minute (RPM), starting with a
3 minutes warming-up at 10 Watts. The test starts at
25 Watts, after which the load is increased by 25 Watts
every 10 seconds. The test ends if cycling speed falls
below 60 RPM. Maximal workload (Wmax), time cycled
at that load, and heart rate at the end of the test are
recorded. The steep ramp test has been shown to be a
reliable (ICC = 0.996) and valid (correlation with peak
oxygen uptake (peakVO2) of 0.85) means of estimating
maximal workload in patients with cancer. PeakVO2 can
be estimated from the steep ramp test using a linear
regression equation [33].
Exercise endurance is measured after a period of rest
following the steep ramp test. The cycle endurance test
is done at a workload based on 70% of the Wmax
reached during the steep ramp test. After a one-minute
warming-up on the same ergometer that was used for
the steep ramp test, the load is increased to the prede-
termined workload. The patient continues cycling at this
constant submaximal workload until the cycling speed
falls below 60 RPM, with a maximum time of 30 min-
utes. The endurance time and heart rate at the end of
the test are recorded. The workload of the endurance
test used at follow up measurements is the same as that
of the baseline endurance test.
Muscle strength
Upper extremity muscle strength is measured with the
JAMAR® grip strength dynamometer [34] and the micro-
FET® hand held dynamometer (HHD) for the elbow flex-
ion, using a standardized measurement protocol [35].
Lower extremity muscle strength is tested with the micro-
FET® HHD for the extension of the knee, again using a
standardized measurement protocol [36], and with the 30
s chair stands test. During the 30 s chair stands test
patients are asked to stand up from a chair with their
arms folded across the chest, then to sit down again. The
action is repeated at their fastest pace over a 30 second
period. The final test score is the number of times that the
patient rises to a full stand from the seated position with
arms folded within 30 s. The 30 s chair stands test has
been shown to be a valid and reliable measure of proximal
lower limb strength in older adults [37].
Fatigue
Fatigue symptoms are assessed with the Multidimen-
sional Fatigue Inventory (MFI) [38]. The MFI is com-
posed of 20 items, organized into five scales: general
fatigue, physical fatigue, reduced activity, reduced moti-
vation, and mental fatigue. Questions are posed about
the past few days, and responses are recorded on a five-
point scale.
In addition to the MFI patients are asked to complete
the Fatigue Quality List (FQL) [39], assessing patients’
perception and appraisal of experienced fatigue. The
FQL consists of 25 adjectives describing the fatigue
experience, organized into 4 subscales: frustrating,
exhausting, pleasant, and frightening.
Secondary study outcomes
Secondary outcomes are mood disturbance, quality of
sleep, health-related quality of life, functioning in daily
life, measured physical activity level, self-reported physi-
cal activity level, anthropometric measures, return to
work, chemotherapy completion rates, compliance, satis-
faction with the intervention, adverse effects and costs
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from a societal perspective. A complete overview of
assessments and instruments are presented in Table 1.
A small selection of these measures is described in
detail.
Measured physical activity level
The level of physical activity will be objectively measured
with the Actigraph (Actigraph, Fort Walton Beach Flor-
ida, USA), a small accelerometer which can measure
accelerations from 0.05 to 2.00 G [40]. These accelera-
tions are scored in counts per minute that provide infor-
mation about how long and how intensive a patient has
been physically active. The epoch will be set at 5 seconds.
Patients wear the accelerometer on the right hip for
5 days including at least one weekend day. The Actigraph
will not give any form of feedback to the participant.
Chemotherapy completion rates
Chemotherapy completion rate will be assessed as the
average relative dose-intensity for the originally planned
regimen based on standard formulas [41]. The data will
be obtained via medical records.
Costs from a societal perspective
For cost-utility purposes, the EQ-5D, a brief HRQoL
measurement, is included in the questionnaire package
[42]. Health care costs, patient and family costs, and
production losses will be assessed, and relevant data will
be collected thought retrospective cost diaries measured
on a monthly basis during the entire study period.
Sociodemographic and clinical data
At baseline, sociodemographic data (e.g., age, gender,
education, marital status, living and work situation), and
lifestyle variables (e.g., smoking history), are being
obtained via questionnaire.
Clinical information, including (date of) diagnosis,
tumor characteristics, treatment (e.g., type of surgery,
chemotherapy regimen), hemoglobin levels and medica-
tion use will be abstracted from the medical records.
During the follow-up period, data on disease status
(progression/recurrence) and any additional treatment
(e.g., endocrine therapy, trastuzumab) is obtained via
medical records and self-report.
Moderating variables
A series of questions is posed to assess potential moder-
ating variables, and variables that may be predictive of
compliance with the physical exercise and activity pro-
grams. These include items assessing attitudes towards
and beliefs about physical activity, social influence from
peers, barriers to and perceived benefits of physical
activity, self-efficay towards physical activity and stage of
Table 1 Outcome measures
Assessment Measurement instrument
Primary Outcome measures
Cardiorespiratory fitness Steep Ramp Test [33]
Endurance Test
Upper Muscle Strength JAMAR® grip strength dynamometer [34]
microFET® HHD elbow flexion [35]
Lower Muscle Strength microFET® HHD extension knee [36]
30 s chair stands test [37]
Fatigue MFI [38]
FQL [39]
Secondary Outcome measures
Mood disturbance Hospital Anxiety and Depression Scale (HADS) [52]
Quality of sleep Pittsburgh Sleep Quality Index (PSQI) [53]
Health-related quality of life EORTC QLQ-C30 [32]
Functioning in daily life Impact on Participation and Autonomy (IPA) [54]
Measured physical activity level Actigraph accelerometer
Self-reported physical activity level Physical Activity Scale for the Elderly (PASE) [55]
Anthropometric measures Skinfold measurements (Harpenden)
Waist and hip circumferences [56]
Return to work Return to work questionnaire
Chemotherapy completion rates Medical records
Compliance Number of sessions attended and activity diary
Satisfaction with the intervention Satisfaction questionnaire
Adverse effects Medical records
Costs from a societal perspective EuroQol EQ5D [42] and monthly cost diaries
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change [43-46]. Patients’ preferences for type of exercise
intervention is also being assessed [21].
Non-participant analysis
In previous studies of exercise programs among patients
with cancer, the generalizability of the results was limited
due to a relatively low participation or uptake rate
[13,14]. We expect that, in the current trial, a substantial
percentage of eligible patients will decline the invitation
to participate in the trial. We hypothesize that patients
who choose not to participate have been less physical
active and have led a more sedentary lifestyle prior to
becoming ill than those who participate. We also expect
that they have less favorable attitudes towards physical
exercise, in general, and during chemotherapy treatment,
in particular. Sociodemographic characteristics, fatigue
and attitudes and behaviors with regard to physical exer-
cise of the non-participants will be compared with those
of the trial participants, using appropriate statistics (e.g.
students t-test, chi square, etc.).
Power calculation
The primary study outcomes include two performance
measures (cardiorespiratory fitness and muscle strength)
and self-reported fatigue. It is expected that patients in
the usual care condition will experience a 5%-10%
decline in physical fitness during their chemotherapy
treatment, that this will improve gradually during the
post-treatment period, but will not necessarily return to
pretreatment levels. It is hypothesized that the OnTrack
program will yield at least a 20% improvement in gen-
eral physical fitness. Based on the results of Courneya
et al., a pretreatment mean for the 1-repetition maxi-
mum for leg extension is estimated to be 25 kg, with a
standard deviation of 12 kg [15]. We expect that the
Onco-Move program will help patients to maintain their
pretreatment levels of cardiorespiratory fitness, but not
necessarily improve, and that it will have little or no
effect on muscle strength.
Based on the above figures, 100 patients per group are
needed to detect a 0.40 standard deviation difference
(Cohen’s effect size [47]) in performance-based out-
comes between the OnTrack group and the usual care
group at the post-chemotherapy assessment, with power
set at 0.80 and alpha at 0.05 (two-sided test).
We will recruit 360 patients into the trial to allow for
an attrition of approximately 20% (i.e., patients who dis-
continue participation in the trial entirely, including fail-
ure to complete follow-up assessments). These numbers
will be sufficient to detect a one-half standard deviation
unit difference in self-reported fatigue. This magnitude
of difference is generally considered to be indicative of
clinically meaningful differences in patients’ self-
reported symptom experience [47,48].
Statistical analyses
All primary statistical analyses will be conducted on an
intention-to-treat basis. Between group differences over
time in performance indicators of general physical con-
dition and muscle strength will be evaluated using mul-
tilevel regression analysis for % change from baseline,
and two factor (group × time) multivariate analysis of
variance with repeated measures on the time factor for
comparison of mean scores. Scores on the self-report
measures of fatigue, mood state and HRQoL will be cal-
culated according to published scoring algorithms.
Between-group differences over time in mean scores will
be tested using a two factor (group × time) multivariate
analysis of variance with repeated measures on the time
factor. Effect sizes will be calculated using standard sta-
tistical procedures.
Supplementary analyses will be carried out in which
data relating to compliance with the program elements
are taken into account. Specifically, we will determine
whether the level of compliance (based on attendance
records and self-report data) is associated significantly
with the changes over time in physical condition, muscle
strength, fatigue, mood, and HRQoL. Similarly, we will
investigate whether program effectiveness varies signifi-
cantly as a function of patients’ background characteris-
tics, and particularly those variables assessing life style,
health behavior and health attitudes.
Cost-effectiveness analysis
This study also includes both incremental cost-effective-
ness and cost-utility analyses. The cost-effectiveness
ratio is calculated by dividing the difference between the
mean total costs of the exercise and control groups by
the difference in mean primary clinical effects of the
groups [49]. In this analysis both direct and indirect
costs will be taken into account. The incremental cost-
utility ratio expresses the additional costs of the inter-
vention per quality-adjusted life year (QALY) gained,
compared to the usual care control group.
Discussion
Compromised physical fitness and increasing fatigue are
common side effects of cancer chemotherapy. Exercise
during chemotherapy is a promising strategy for inter-
vening at any earlier stage, to minimize or even prevent
side effects both in the short- and long-term. Previous
studies investigating the value of physical exercise dur-
ing treatment have yielded inconsistent results, and
many studies exhibited a range of methodological
limitations.
In the current trial, we are evaluating the effectiveness
and cost-effectiveness of a low intensity, home-based
physical activity program, and a structured, supervised,
moderate intensity exercise program in maintaining or
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enhancing physical fitness (cardiorespiratory fitness and
muscle strength), in minimizing fatigue, and in enhan-
cing HRQoL of patients undergoing adjuvant che-
motherapy for breast cancer or colon cancer.
Our trial has several strengths, including: (1) the ran-
domized trial design; (2) the multicenter nature of the
trial; (3) the large sample size; (4) the relatively long-
term follow-up; (5) the head-to-head comparison of two
interventions varying in nature and intensity; (6) inclu-
sion of both performance based and self-reported out-
comes; (7) the use of intention-to-treat analysis; (8) the
inclusion of a cost-effectiveness and cost-utility evalua-
tion; and (9) the detailed evaluation of the background,
attitudes and behavior of patients who decline to partici-
pate in the trial.
Several limitations of the trial should also be noted.
First, although direct peakVO2 measurements are con-
sidered the gold standard for assessing cardiorespiratory
fitness, these are not feasible in our trial because of the
number and geographical spread of the training loca-
tions, and the (travel) time and costs involved with cen-
tralized measurements. However, it can be argued that
an improvement in cycle endurance time may be more
clinically relevant than an improvement in peakVO2
[50,51]. Second, although the usual care control group
will not be provided with any materials or programs ele-
ments relating to physical exercise, clinicians and ancil-
lary health care providers are increasingly recognizing
the potential value of physical activity both during and
following cancer treatment. Thus we cannot rule out
the possibility that some patients in the control group
will be encouraged to increase their level of physical
activity, either by their caregivers or via the media.
Nevertheless, we do not anticipate that this will take
place in a structured or systematic way, and thus the
planned comparisons (between the two intervention
groups and the control group) will still be valid.
In summary, given the increasing number of patients
with cancer, and improving survival rates, it is important
to ensure that patients’ physical and psychosocial health
is maintained or even enhanced to as great an extent as
possible both during active treatment and once treat-
ment has been completed. Encouraging and facilitating
physical activity during treatment may enhance health
outcomes in both the short- and long-term.
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